Pomerantz LLP is investigating claims on behalf of investors of Calumet, Inc. (“Calumet” or the “Company”) (NASDAQ: CLMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Calumet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 7, 2026, Calumet reported its financial results for the second quarter of 2026. Among other items, Calumet disclosed that its Performance Brands segment saw adjusted EBITDA decline by $6.2 million year-over-year due to timing issues, as input costs spiked before pricing actions caught up, with a $7 million LIFO accounting headwind; that its Montana Renewables business’s results were impacted by over $40 million of foregone margin due to downtime from the MaxSAF expansion and turnaround, limiting its contribution to $17 million of adjusted EBITDA; and that the Company is deferring the full ramp-up of SAF production to capture an extra $50 million of EBITDA at the conventional refinery (CMR) before reconfiguring assets, which delays the realization of higher SAF yields and volumes.
On this news, Calumet’s stock price fell $2.40 per share, or 5.73%, to close at $39.48 per share on August 7, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.